Quality Tech Articles & Tips
[ad_1] This year’s presidential election is already sending health-care stocks on a wild ride. Historically, shifts in political control have created “increased volatility” across the health care sector, sending investors “to look for areas of safety,” Raymond James analyst Chris Meekins said in a July 7 note. “This election is likely to produce distinct, binary,…
[ad_1] Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024…
[ad_1] Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies…
[ad_1] AbbVie on Wednesday said it will acquire neuroscience drugmaker Cerevel Therapeutics for roughly $8.7 billion. Under the terms of the deal, AbbVie will pay $45 per share for Cerevel. AbbVie said it expects to complete the acquisition in the middle of 2024. Shares of Cerevel jumped 16% after the close Wednesday to nearly $43…
[ad_1] Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for…
[ad_1] Biopharma companies are having more clinical success treating Alzheimer’s disease and obesity and are taking new approaches in oncology, and that’s creating more mega-blockbuster drugs, according to Bank of America. Analyst Geoff Meacham has identified 20 drugs that have the potential to generate $10 billion or more in annual sales by 2030 within the…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. Market still oversold When to buy chip Quick mentions: TJX, DIS, ABBV 1. Market still oversold We’re finally saying goodbye to September — but likely not to all the…
[ad_1] Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. We’re letting our stocks run on Fed day Companies with pricing power are winners here Quick mentions: CSCO, NVDA, QCOM, MRVL, CRM 1. We’re letting our stocks run on…
[ad_1] A pharmacist collects medications for prescriptions at a pharmacy. Simon Dawson | Bloomberg | Getty Images Medicare is poised to renegotiate the prices of some of its most expensive drugs through a historic expansion of its power, which could reduce costs for many seniors as well as federal spending on its prescription drug plan….